혈액암 (AML/ALL) | 바이오정보모아

CGTAHOTFDACuratedFDABiologicNovartisApproved

tisagenlecleucel (Kymriah, tisa-cel)

ALL, DLBCL, FL · CD19

#CD19#CGT#Approved#FDA승인#바이오정보모아추천+5

효능 ORR 82.3%임상시험 48상태 APPROVED

ADCSFDAFDABiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Fam-Trastuzumab Deruxtecan-Nxki)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · HER2

#HER2#ADC#Phase2#FDA승인#항체약물접합체+4

효능 ORR 71.7%임상시험 23상태 RECRUITING

ADCAFDAFDABiologicstaleAbbViePhase 3

Telisotuzumab Vedotin (Telisotuzumab Vedotin)

Advanced Solid Tumors Cancer · Non Small Cell Lung Cancer

#NonSmallCellLungCancer#ADC#Phase3#FDA승인#항체약물접합체+3

효능 ORR 33.3%임상시험 12상태 RECRUITING

CGTAAVBHOTFDACuratedFDABiologicSpark TherapeuticsHuman RPE65 cDNAApproved

voretigene neparvovec (Luxturna, AAV2-hRPE65v2, voretigene neparvovec-rzyl)

Inherited retinal dystrophy due to confirmed biallelic RPE65 mutations · RPE65 (AAV2)

#RPE65AAV2#CGT#Approved#FDA승인#바이오정보모아추천+5

임상시험 7상태 APPROVED

AntibodyHotRochePhase 3

atezolizumab (Tecentriq)

Advanced Solid Tumor · Thoracic Neoplasms, Lung Diseases, Small

#ThoracicNeoplasmsLungDiseasesSma#Antibody#Phase3#인기#항체+5

효능 ORR 95%임상시험 655상태 RECRUITING

ADCBHotBiologicAcademic and Community Cancer R…Phase 3

Lenvatinib (Lenvatinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · Solid Tumor

#SolidTumor#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 70.3%임상시험 164상태 RECRUITING

AntibodyAHotRocheApproved

Tocilizumab (Tocilizumab)

Multiple Myeloma (MM); Multiple Myeloma Refractory · Chronic Lymphocytic Leukemia

#ChronicLymphocyticLeukemia#Antibody#Approved#인기#항체+5

효능 ORR 95%임상시험 141상태 RECRUITING

ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5

효능 ORR 50%임상시험 135상태 RECRUITING

AntibodyCHotBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5

효능 ORR 37.1%임상시험 125상태 RECRUITING

AntibodyAHotMerck KGaAvedotin (EV) was the most c…Phase 3

Avelumab (Avelumab)

Non Small Cell Lung Cancer; Colorectal Cancer · Locally Advanced or Metastatic Urothelia

#LocallyAdvancedorMetastaticUroth#Antibody#Phase3#인기#항체+5

효능 ORR 74%임상시험 123상태 ACTIVE

ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5

효능 ORR 80%임상시험 119상태 RECRUITING

AntibodyCHotstaleXin-Hua XuPhase 2

AK104 (Cadonilimab, Cadonilimab (AK104))

Non-small Cell Lung Cancer · Leptomeningeal Metastasis

#LeptomeningealMetastasis#Antibody#Phase2#인기#항체+5

임상시험 101상태 RECRUITING

CGTABiologicstaleAstraZenecaPhase 2

autologous CD19-directed chimeric antigen receptor (CAR, autologous CD19-directed chimeric antigen receptor, autologous CD19-directed chimeric antigen receptor (CAR) T-cells)

Relapsed Non Hodgkin Lymphoma; Relapsed Adult ALL · CD19

#CD19#CGT#Phase2#인기#세포유전치료+5

효능 ORR 77.3%임상시험 96상태 RECRUITING

ADCBBiologicstaleGileadPhase 2

SG (Sacituzumab Govitecan-hziy, Sacituzumab Govitecan-hziy (SG))

Lung Cancer; Advanced or Metastatic Non-Small-Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 34.3%임상시험 94상태 RECRUITING

ADCCBiologicstaleCelgenePhase 2

5-Azacytidine (5-Azacytidine)

Leukemia · Leukemia

#Leukemia#ADC#Phase2#인기#항체약물접합체+2

효능 ORR 75%임상시험 89상태 DISCONTINUED

ADCCBiologicstaleAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 59%임상시험 89상태 DISCONTINUED

AntibodyAstaleRochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5

효능 ORR 76.7%임상시험 88상태 ACTIVE

ADCABiologicstaleJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4

효능 ORR 76.7%임상시험 88상태 RECRUITING

ADCBBiologicstaleDaiichi SankyoPhase 2

Fixed dose (Patritumab Deruxtecan, Patritumab Deruxtecan (Fixed dose))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+4

효능 ORR 64%임상시험 88상태 RECRUITING

ADCBBiologicstaleDaiichi Sankyoderuxtecan, sacituzumab gov…Phase 2

Up-Titration (Patritumab Deruxtecan, Patritumab Deruxtecan (Up-Titration))

Non-Small Cell Lung Cancer Metastatic; Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor · Non-Small Cell Lung Cancer Metastatic

#Non-SmallCellLungCancerMetastati#ADC#Phase2#인기#항체약물접합체+5

효능 ORR 64%임상시험 88상태 RECRUITING

1 / 39 페이지

← 이전다음 →